News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,240 Results
Type
Article (41252)
Company Profile (403)
Press Release (651585)
Section
Business (207905)
Career Advice (1989)
Deals (35918)
Drug Delivery (85)
Drug Development (83036)
Employer Resources (168)
FDA (16223)
Job Trends (15017)
News (350968)
Policy (32944)
Tag
Academia (2617)
Africa (728)
Alliances (50457)
Alzheimer's disease (1177)
Approvals (16156)
Arizona (177)
Artificial intelligence (69)
Asia (38114)
Australia (6315)
Bankruptcy (359)
Best Places to Work (11423)
Biosimilars (63)
Biotechnology (300)
C2C Services and Suppliers (79632)
California (1718)
Canada (866)
Cancer (351)
Career advice (1658)
Cell therapy (112)
China (121)
Clinical research (64700)
Collaboration (123)
Colorado (67)
Compensation (61)
Connecticut (67)
COVID-19 (2537)
Cystic fibrosis (76)
Data (171)
Diabetes (72)
Diagnostics (6007)
Drug pricing (69)
Earnings (84833)
Employer resources (143)
Europe (82875)
Events (110918)
Executive appointments (115)
FDA (16407)
Florida (232)
Funding (114)
Gene therapy (91)
GLP-1 (531)
Government (4367)
Healthcare (18904)
Hotbed/Location (488272)
Illinois (249)
Indiana (138)
Infectious disease (2561)
Inflammatory bowel disease (92)
Interviews (305)
IPO (16448)
Job creations (3688)
Job search strategy (1422)
Kansas (95)
Layoffs (417)
Legal (7902)
Lung cancer (77)
Manufacturing (75)
Maryland (369)
Massachusetts (1455)
Medical device (13164)
Medtech (13167)
Mergers & acquisitions (19286)
Metabolic disorders (238)
Michigan (118)
Minnesota (212)
Neuroscience (1309)
New Jersey (513)
New York (531)
NextGen Class of 2024 (6703)
Non-profit (4519)
North Carolina (624)
Northern California (755)
Obesity (146)
Ohio (99)
Opinion (186)
Patents (64)
Pennsylvania (542)
People (57087)
Pharmaceutical (78)
Phase I (20222)
Phase II (28557)
Phase III (21171)
Pipeline (99)
Postmarket research (2583)
Preclinical (8683)
Press Release (67)
Rare diseases (125)
Real estate (5985)
Recruiting (64)
Regulatory (21574)
Research institute (2395)
Resumes & cover letters (347)
South America (1098)
Southern California (679)
Startups (3739)
Texas (210)
United States (8027)
Vaccines (466)
Washington State (247)
Weight loss (130)
Date
Today (6)
Last 7 days (596)
Last 30 days (2073)
Last 365 days (38263)
2024 (25807)
2023 (41013)
2022 (52276)
2021 (56766)
2020 (54924)
2019 (47419)
2018 (35698)
2017 (33026)
2016 (32347)
2015 (38398)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
693,240 Results for "protagonist therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York City on June 4-6, 2024.
May 31, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics to Participate in Upcoming March 2024 Investor Conferences
Protagonist Therapeutics, Inc. announced that they will participate in three upcoming investor conferences.
March 6, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Association (EHA) Congress being held in Madrid, Spain from June 13-16, 2024.
May 14, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Protagonist Therapeutics, Inc. announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024.
March 18, 2024
·
1 min read
Business
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics (NASDAQ:PTGX) (“Protagonist” or “the Company”) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 7, 2024
·
11 min read
Biotech Bay
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor meetings at the Citizens JMP Life Sciences Conference being held in New York City on May 13-14, 2024.
May 7, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Protagonist Therapeutics, Inc. announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera as of and expects to meet the trial’s 250 patient enrollment target by the end of March 2024.
March 26, 2024
·
5 min read
Drug Development
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Protagonist Therapeutics, Inc. announced details from two abstracts at the European Hematology Association 2024 Congress, including an oral presentation with long-term follow-up data from the Phase 2 REVIVE study with rusfertide, a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera and other disease indications.
June 14, 2024
·
7 min read
Biotech Bay
Protagonist Therapeutics Reports Granting of Inducement Awards - February 20, 2024
Protagonist Therapeutics, Inc. reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company’s recently hired Vice President and Controller, in accordance with the terms of Mr. Reddy’s employment offer letter.
February 20, 2024
·
2 min read
Press Releases
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
September 3, 2024
·
2 min read
1 of 69,324
Next